2-phenyl-oct-1-en-3-one | 143676-05-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-phenyl-oct-1-en-3-one
• 英文别名: 2-phenyloct-1-en-3-one
• CAS: 143676-05-5
• 化学式: C₁₄H₁₈O
• 分子量: 202.296
• InChiKey: UXDQSXGJWVQBON-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-phenyl-oct-1-en-3-one 在 一水合肼 作用下， 以 乙醇 为溶剂， 反应 4.0h， 生成 3-(n-pentyl)-4-phenyl-4,5-dihydropyrazole
  参考文献：
  名称：

  新型吡唑啉甲酰胺两类不同的有效大麻素CB 1受体激动剂

  摘要：

  的3-烷基-4-芳基-4,5-二氢吡唑-1-羧酰胺的合成和SAR 1 - 23和1-烷基-5-芳基-4,5-二氢吡唑-3-甲酰胺24 - 27作为两个新的大麻素描述了CB 1受体激动剂类别。目标化合物引起对CB 1和CB 2受体的高亲和力，并被发现可作为CB 1受体激动剂。关键化合物19在体外引起强效的CB 1激动剂和CB 2反向激动剂特性，并且在啮齿动物模型中口服给药后在多发性硬化中表现出体内活性。

  DOI：

  10.1016/j.bmcl.2010.07.056
• 作为产物：
  描述：

  β-硝基苯乙烯 、 alkaline earth salt of/the/ methylsulfuric acid 生成 2-phenyl-oct-1-en-3-one
  参考文献：
  名称：

  1,1-锌，硼和1,1-铜，烯基硼双金属化合物的制备及反应

  摘要：

  通过1-碘炔烃的硼氢化反应容易制得的频哪醇α-碘烯基硼酸酯8被转化为硼和锌或铜的1，1-双金属化合物，它们与各种各样的亲电试剂反应，得到多官能的硼酸酯。在H 2 O 2氧化（30％H 2 O 2，饱和NaOAc水溶液）之后，以良好或优异的产率制备了多官能酮。

  DOI：

  10.1016/0040-4039(92)80007-7

文献信息

• 4,5-Dihydro-(1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators
  申请人：Lange H.M. Josephus

  公开号：US20070142362A1

  公开（公告）日：2007-06-21

  This invention is directed to 4,5-dihydro-(1H)-pyrazole(pyrazoline) derivatives as cannabinoid CB 1 receptor modulators, to pharmaceutical compositions containing these compounds, to methods for the preparation of these compounds, methods for preparing novel intermediates useful for their synthesis, and methods for preparing compositions. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in disorders in which CB 1 receptors are involved, or that can be treated via manipulation of those receptors. The compounds have the general formula (I) wherein the symbols have the meanings given in the specification.

  这项发明涉及作为大麻素CB1受体调节剂的4,5-二氢-(1H)-吡唑烯(吡唑啉)衍生物，含有这些化合物的药物组合物，制备这些化合物的方法，用于制备其合成有用的新中间体的方法，以及制备组合物的方法。该发明还涉及这些化合物和组合物的用途，特别是它们在向患者施用以在涉及CB1受体的疾病中实现治疗效果，或者可以通过操纵这些受体来治疗的疾病中的用途。 这些化合物具有通式(I) 其中符号的含义如规范中所述。
• NOVEL COCRYSTALLIZATION
  申请人：CHILDS Scott L.

  公开号：US20090281195A1

  公开（公告）日：2009-11-12

  The present disclosure relates to novel cocrystals and novel methods for cocrystallization. In particular, the disclosure includes cocrystals comprising a salt of an active agent, such as a chloride salt of an active pharmaceutical ingredient. The present disclosure also relates to methods of preparing cocrystals and methods for screening for solid state phases.

  本公开涉及新型共晶体和新型共晶化方法。具体而言，公开包括由活性剂的盐组成的共晶体，例如活性药物成分的氯化物盐。本公开还涉及制备共晶体的方法和筛选固态相的方法。
• 4,5-DIHYDRO- (1H)-PYRAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR MODULATORS
  申请人：Abbott Healthcare Products B.V.

  公开号：EP1966146B1

  公开（公告）日：2011-03-02
• Cocrystallization methods
  申请人：Childs Scott

  公开号：US20070088508A1

  公开（公告）日：2007-04-19

  Methods for preparing cocrystals wherein solutions of active agents in suitable liquids are combined with solutions of guests, both with and without suitable liquids, in an interface region are described herein. Methods for analyzing the cocrystals are also described.
• Screening For Solid Forms By Ultrasound Crystallization And Cocrystallization Using Ultrasound
  申请人：Childs L. Scott

  公开号：US20070287194A1

  公开（公告）日：2007-12-13

  The present disclosure relates to crystallizing a chemical substance(s) using ultrasound. Methods are provided for screening a chemical substance according to its solid forms by using ultrasound to generate new or unusual solid forms. Methods are also provided for crystallizing a chemical substance by novel techniques that include sonication. The present disclosure also relates to cocrystallization using ultrasound. Methods are provided for preparing cocrystals of an active agent and a guest by sonicating and crystallizing. Methods are also provided for screening a sample according to solid state phases (such as cocrystals and salts) and include generating a cocrystal from the sample using ultrasound.